FindTrial
Sign In

SBRT combined with DC-CIK immunotherapy in advanced none-small cell lung cancer after failure of second-line therapy

A prospective, single arm, multicenter study: assessment of efficacy and safety of SBRT combined with DC-CIK immunotherapy in advanced none-small cell lung cancer after failure of second-line therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-16008786
Enrollment
Unknown
Registered
2016-07-06
Start date
2016-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

single arm:treatment

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technolog
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Histologically or cytologically confirmed diagnosis of none-small cell lung cancer; (2) Clinical stage IV accodring to AJCC Cancer Staging (Version 7); (3) Failure of second-line chemotherapy or targeted therapy; (4) Long diameter of >=2 measurement of disease >1.5 cm; (5) Aged more than 18 years; (6) ECOG performance status 3.5×10^9/L, hemoglobin > 90g/L and platelets > 100×10^9/L; (8) Normal renal function: Creatinine clearance > 60 ml/min; (9) Pulmonary function: (1) FEV1>30%, (2) DLCO>30%; (10) Signed written informed consent.

Exclusion criteria

Exclusion criteria: (1) Previous treatment including chemotherapy, radiotherapy, biological targeted therapy and immunotherapy within 4 weeks; (2) Expected survival time 3s or APTT > 10s; (4) A history of severe allergic reactions; (5) Pregnant and/or breastfeeding. Patients of childbearing potential must have a negative pregnancy test. Effective methods of contraception should be carried out during treatment; (6) Patients with other serious intercurrent illness including unstable angina which would interfere with drug, renal disease, chronic hepatitis, uncontrolled diabetes (fasting blood-glucose > 1.5×ULN), HIV/AIDS, uncontrolled infections and mental disorders; (7) Not suitable to be enrolled in the trial in the opinion of the investigator.

Design outcomes

Primary

MeasureTime frame
Efficacy;—

Secondary

MeasureTime frame
Overal survival;Progression-free survival;Time to progress;???????;Circulating tumor cell in peripheral blood;Treatment-related adverse effects;Quality of life;—

Countries

China

Contacts

Public ContactYang Kunyu

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

yangky71@aliyun.com+86 13995595360

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026